Words by Isabel O’Brien
Lindy Biosciences has announced an exclusive global licensing agreement and strategic collaboration with Novartis Pharma AG. The deal centres on Lindy’s microglassification technology, which facilitates high-concentration subcutaneous injections of biologic drugs, enabling more convenient self-administration.
This innovation is expected to significantly improve patient outcomes and treatment compliance by allowing patients to administer high doses of biologics at home, potentially reducing healthcare costs.
Under the terms of the agreement, Lindy Biosciences will receive an upfront payment of 20m (USD) from Novartis. In addition, Lindy is eligible for up to 934m (USD) in milestone payments, along with tiered royalties on net sales. This partnership aims to transform the way biologic drugs are delivered, particularly focusing on shifting from intravenous to subcutaneous administration.
Dr Deborah Bitterfield, CEO, Lindy Biosciences, expressed her enthusiasm for the collaboration, stating: “This collaboration is a testament to our shared dedication to enhancing patient care and marks a significant milestone as we take Lindy’s formulation technology into the clinic for the first time.”
By leveraging this innovative technology, the partnership could broaden access to biologic treatments and enhance patient care across various therapeutic areas.
